WO2000022124A3 - Methods and compositions to induce antitumor response - Google Patents

Methods and compositions to induce antitumor response Download PDF

Info

Publication number
WO2000022124A3
WO2000022124A3 PCT/US1999/021454 US9921454W WO0022124A3 WO 2000022124 A3 WO2000022124 A3 WO 2000022124A3 US 9921454 W US9921454 W US 9921454W WO 0022124 A3 WO0022124 A3 WO 0022124A3
Authority
WO
WIPO (PCT)
Prior art keywords
cells
compositions
present
dendritic
induce
Prior art date
Application number
PCT/US1999/021454
Other languages
French (fr)
Other versions
WO2000022124A2 (en
Inventor
Drake M Laface
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Priority to AU64977/99A priority Critical patent/AU6497799A/en
Publication of WO2000022124A2 publication Critical patent/WO2000022124A2/en
Publication of WO2000022124A3 publication Critical patent/WO2000022124A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

(57) Abstract The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize, differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells). The present invention provides a method to induce an antitumor immune response through the use of such compositions.
PCT/US1999/021454 1998-10-15 1999-10-14 Methods and compositions to induce antitumor response WO2000022124A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64977/99A AU6497799A (en) 1998-10-15 1999-10-14 Methods and compositions to induce antitumor response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17320398A 1998-10-15 1998-10-15
US09/173,203 1998-10-15

Publications (2)

Publication Number Publication Date
WO2000022124A2 WO2000022124A2 (en) 2000-04-20
WO2000022124A3 true WO2000022124A3 (en) 2000-07-06

Family

ID=22630966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/021454 WO2000022124A2 (en) 1998-10-15 1999-10-14 Methods and compositions to induce antitumor response

Country Status (2)

Country Link
AU (1) AU6497799A (en)
WO (1) WO2000022124A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229621B2 (en) 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
US7361329B2 (en) 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
AU2002225927A1 (en) * 2000-11-17 2002-05-27 Immunex Corporation Chemoattractant recruitment of dendritic cells for enhancement of immunization
CA2439185A1 (en) 2001-02-23 2002-09-06 Novartis Ag Vector constructs
CN106913865A (en) 2013-04-18 2017-07-04 阿尔莫生物科技股份有限公司 The method that disease and illness are treated using interleukin 10
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011984A2 (en) * 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
US5677178A (en) * 1993-02-16 1997-10-14 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1998015285A1 (en) * 1996-10-10 1998-04-16 The Wistar Institute Of Anatomy And Biology Methods and compositions for inducing a protective immune response to cancers
WO1998021330A1 (en) * 1996-11-15 1998-05-22 Indiana University Foundation Exodus chemokine materials and methods
WO1998021228A1 (en) * 1996-11-15 1998-05-22 Canji, Inc. Tissue specific expression of retinoblastoma protein
WO1998039464A2 (en) * 1997-03-03 1998-09-11 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO1999047169A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Methods to provoke anti-cancer immune responses

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677178A (en) * 1993-02-16 1997-10-14 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1995011984A2 (en) * 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
WO1998015285A1 (en) * 1996-10-10 1998-04-16 The Wistar Institute Of Anatomy And Biology Methods and compositions for inducing a protective immune response to cancers
WO1998021330A1 (en) * 1996-11-15 1998-05-22 Indiana University Foundation Exodus chemokine materials and methods
WO1998021228A1 (en) * 1996-11-15 1998-05-22 Canji, Inc. Tissue specific expression of retinoblastoma protein
WO1998039464A2 (en) * 1997-03-03 1998-09-11 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO1999047169A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Methods to provoke anti-cancer immune responses

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DIEU M-C ET AL.: "Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 2, 20 July 1998 (1998-07-20), pages 373 - 386, XP002133972 *
HE X-S ET AL.: "Construction of adenoviral and retroviral vectors coexpressing the genes encoding the hepatitis B surface antigen and B7-1 protein", GENE, vol. 175, no. 1/2, 10 October 1996 (1996-10-10), pages 121 - 125, XP002041764 *
ISHIDA T ET AL.: "Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 117, no. 2, August 1999 (1999-08-01), pages 244 - 251, XP000891464 *
SHERMAN L A ET AL.: "Strategies for tumor elimination by cytotoxic T lymphocytes", CRITICAL REVIEWS IN IMMUNOLOGY, vol. 18, no. 1-2, 1998, pages 47 - 54, XP000877347 *
SONG W ET AL.: "Dendritic cells genetically modified with and adenovirus vector encoding the cDNA for a model antigen induce protective", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 8, 20 October 1997 (1997-10-20), pages 1247 - 1256, XP002133971 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Also Published As

Publication number Publication date
AU6497799A (en) 2000-05-01
WO2000022124A2 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
ES2265980T5 (en) METHODS RELATED TO INTERFERON INDUITED BY IMMUNE STIMULATING NUCLEIC ACIDS.
CA2182303A1 (en) Method of preparing a viral vector by homologous intermolecular recombination
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
CA2267157A1 (en) Cancer immunotherapy using tumor cells combined with mixed lymphocytes
EP1923467A3 (en) Adenovirus vectors for gene therapy
PL337019A1 (en) Peptide-coated implants and method of obtaining them
WO1999061601A3 (en) Aav5 vector and uses thereof
EP0584266A4 (en) Recombinant virus expressing carcinoembryonic antigen and methods of use thereof.
AU4078599A (en) Expression vectors for stimulating an immune response and methods of using the same
WO1995024485A3 (en) Coordinate in vivo gene expression
CZ63995A3 (en) Virus vectors and their use in gene therapy
WO2002049669A3 (en) Electrically responsive promoter system
HK1031097A1 (en) Processes for preparing nucleic acid constructs
WO1999062923A3 (en) Immunostimulatory oligonucleotides with modified bases and methods of use thereof
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
CA2323086A1 (en) Regulation of endogenous gene expression in cells using zinc finger proteins
WO1999029341A3 (en) Methods for enhancement of protective immume responses employing leishmania polypeptides
WO1998034952A3 (en) Il-2 gene expression and delivery systems and uses
IL135688A0 (en) Human checkpoint kinase, hcds1, compositions and methods
WO2000022124A3 (en) Methods and compositions to induce antitumor response
WO1999024077A3 (en) Compositions and methods for targeted delivery of biologically-active factors
EP1591528A3 (en) Method and compositions for delivery and expression of interferon-alpha nucleic acids
SI1212428T1 (en) Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
WO2000001835A3 (en) Targeted integration into chromosomes using retroviral vectors
WO1996040764A3 (en) Nucleotide and amino acid sequences of hypervariable region 1 of the envelope 2 gene of hepatitis c virus

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 64977

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase